Akebia Therapeutics (AX9) Ownership - Who Owns Akebia Therapeutics?
Akebia Therapeutics (AX9) Ownership Overview
- 2.89% Insiders
- 8.58% Mutual Funds
- 0.39% Other Institutional Investors
- 11.21% ETFs
- 76.93% Public Companies and Individual Investors
The ownership structure of Akebia Therapeutics (CH:AX9) stock is a mix of institutional, retail, and individual investors. Approximately 20.18% of the company’s stock is owned by Institutional Investors, 2.89% is owned by Insiders, and 76.93% is owned by Public Companies and Individual Investors.
The ownership structure of Akebia Therapeutics (CH:AX9) stock is a mix of institutional, retail, and individual investors. Approximately 20.18% of the company’s stock is owned by Institutional Investors, 2.89% is owned by Insiders, and 76.93% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Jun 30, 2026 | Erik Ostrowski | $62,181 | |
| Mar 04, 2026 | John P. Butler | $86,588 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Entrypoint Capital, Llc | CHF205,276 | |
| Dec 31, 2025 | Graham Capital Management, L.p. | CHF606,268 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 19,986,374 | Institution | 7.21% | ― |
| Vanguard | 14,010,994 | Institution | 5.06% | ― |
| Vanguard Index Funds | 11,077,167 | Institution | 4.00% | ― |
| Ishares | 10,864,038 | Institution | 3.92% | ― |
| John P. Butler | 3,878,492 | Insider | 1.40% | ― |
| Fidelity Salem Street Trust | 3,104,905 | Institution | 1.12% | ― |
| Fidelity | 2,023,685 | Institution | 0.73% | ― |
| Vanguard Scottsdale Funds | 1,777,919 | Institution | 0.64% | ― |
| Fidelity Concord Street Trust | 1,769,912 | Institution | 0.64% | ― |
| Schwab | 1,676,073 | Institution | 0.60% | ― |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 11,077,167 | Institution | 4.00% | ― |
| Fidelity Salem Street Trust | 3,104,905 | Institution | 1.12% | ― |
| Vanguard Scottsdale Funds | 1,777,919 | Institution | 0.64% | ― |
| Fidelity Concord Street Trust | 1,769,912 | Institution | 0.64% | ― |
| Schwab Capital Trust | 801,632 | Institution | 0.29% | ― |
| Vanguard World Fund | 763,706 | Institution | 0.28% | ― |
| Aqr Funds | 607,071 | Institution | 0.22% | ― |
| Columbia Funds Series Trust I | 588,065 | Institution | 0.21% | ― |
| Tiaa-cref Funds | 537,795 | Institution | 0.19% | ― |
| Fidelity Commonwealth Trust Ii | 396,648 | Institution | 0.14% | ― |
FAQ
Who Owns Akebia Therapeutics (CH:AX9)?
According to the latest TipRanks data, approximately 20.18% of the company's stock is held by institutional investors, 2.89% is held by insiders, and 76.93% is held by public companies and individual investors.
What percentage of Akebia Therapeutics (CH:AX9) stock is held by institutional investors?
According to the latest TipRanks data, approximately 20.18% of Akebia Therapeutics (CH:AX9) stock is held by institutional investors: 8.58% by mutual funds, 11.21% by ETFs and 0.39% by other institutional investors.
What percentage of Akebia Therapeutics (CH:AX9) stock is held by retail investors?
According to the latest TipRanks data, approximately 76.93% of Akebia Therapeutics (CH:AX9) stock is held by public companies and individual investors.
Who owns the most shares of Akebia Therapeutics (CH:AX9)?
BlackRock, Inc. owns the most shares of Akebia Therapeutics (CH:AX9).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
